Search results
Showing 2651 to 2700 of 3803 results for treatment
alcohol-related problems. However, even with the most effective current treatment (for example, cognitive behavioural therapies and...
End of life care for infants, children and young people (QS160)
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS160Show all sections
Sections for QS160
- Quality statements
- Quality statement 1: Advance care plan
- Quality statement 2: Named medical specialist
- Quality statement 3: Emotional and psychological support
- Quality statement 4: Specialist paediatric palliative care team
- Quality statement 5: Support for grief and loss for parents or carers
- Quality statement 6: Care at home
- About this quality standard
Flexible endoscopic treatment of a pharyngeal pouch (IPG513)
We have moved interventional procedures guidance 513 to become HealthTech guidance 367. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
This quality standard covers oral health, including dental health and daily mouth care, for adults in care homes (with and without nursing provision). It describes high-quality care in priority areas for improvement.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
key outcomes should include symptoms, relapse rates, quality of life, treatment acceptability, experience of care, level of psychosocial...
For isoniazid-resistant TB, what is the most effective regimen for reducing mortality andmorbidity?
applicable) Why this is important There is little evidence for the treatment of isoniazid resistant TB. This is the most common form of...
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...
recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...
This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)
Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.
Leukomed Sorbact for preventing surgical site infection (HTG567)
Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery.
Evidence-based recommendations on radiofrequency-assisted liver resection. This involves using high-frequency radio waves to remove the cancerous part of the liver with minimal blood loss.
View recommendations for HTG136Show all sections
Sections for HTG136
LiMAx system for assessing the functional capacity of the liver (MIB168)
NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .
Read biographies for all members of NICE's indicator advisory committee.
Read biographies for all members of NICE's indicator advisory committee.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
include local control, progression-free survival, overall survival, and treatment-related morbidity and mortality. In a very small...
Our forward view highlights the areas we will prioritise in the coming year.
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
Boston Keratoprosthesis Type I for corneal blindness (MIB91)
NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .
DOAC Dipstick for detecting direct oral anticoagulants (MIB248)
NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .
Alteplase for the treatment of acute ischaemic stroke (TA122)
This guidance has been updated and replaced by NICE technology appraisal guidance 264 issued in September 2012.
Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Cryotherapy as a primary treatment for prostate cancer (IPG145)
We have moved interventional procedures guidance 145 to become HealthTech guidance 91. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Microwave ablation for the treatment of liver metastases (IPG406)
Interventional procedures, IPG406 - Issued: August 2011 --> This guidance has been updated and replaced by NICE interventional procedure guidance 553.
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
Trabectedin for the treatment of relapsed ovarian cancer (TA222)
This guidance has been updated and replaced by NICE technology appraisal guidance 389.
Ranibizumab for the treatment of diabetic macular oedema (TA237)
This guidance has been updated and replaced by NICE technology appraisal guidance 274.
Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)
This guidance has been replaced by NICE technology appraisal guidance 474.
Awaiting development Reference number: GID-TA11826 Expected publication date: TBC
the comparative efficacy and safety of different surgical and ablative treatments would be useful. Any explanatory notes(if applicable)...
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
Evidence-based recommendations on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI in adults. This involves placing a device inside an artery near the heart.
View recommendations for HTG515Show all sections
This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.
View quality statements for QS167Show all sections
Sections for QS167
- Quality statements
- Quality statement 1: Designing health and wellbeing programmes
- Quality statement 2: Peer and lay roles
- Quality statement 3: Referring people at high risk of type 2 diabetes
- Quality statement 4: Cardiac rehabilitation
- Quality statement 5: Support for people with mental health problems
- Quality statement 6: Physical health checks for people with serious mental illness
- Update information
Vagus nerve stimulation for treatment-resistant depression (IPG330)
This guidance has been updated and replaced by NICE HealthTech guidance 551.
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG770)
Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias. This involves implanting a cardiac pacemaker that does not have leads directly into the internal wall of the heart.
View recommendations for HTG770Show all sections
sertraline and cognitive behavioural therapy (CBT) are efficacious in the treatment of generalised anxiety disorder (GAD) but their...
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.
Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)
This guidance has been updated and replaced by NICE guideline NG156.
that clear treatment goals that will positively influence the child or young person's life should be identified before offering this...
Liver disease:- Should all children with meconium ileus receive ursodeoxycholic acid from diagnosis?
meconium ileus are at an increased risk of liver disease, and starting treatment with ursodeoxycholic acid from diagnosis may reduce...
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Rimonabant for the treatment of overweight and obese adults (TA144)
This appraisal has been withdrawn. This is because the marketing authorisation for rimonabant was withdrawn on 16 January 2009.
Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)
This guidance has been replaced by NICE technology appraisal guidance 199.